Nineteen young human immunodeficiency virus-infected patients were randomized to receive 400 mg of oral diethyldithiocarbamate (DTC) per m2 or placebo weekly for 12 weeks. Changes in blood CD4+ lymphocytes were not significantly different between groups. However, neutrophil, monocyte, and platelet counts consistently decreased during DTC treatment, suggesting DTC-mediated myelosuppression.
A report that diethyldithiocarbamate (DTC) recruited functional T lymphocytes in children undergoing immunosuppressive treatment for cancer (7) has prompted several clinical trials of this drug as a possible therapy for human immunodeficiency virus (HIV)-infected adults. To assess the safety and estimate the efficacy of DTC in HIV-infected children, adolescents, and young adults, we conducted a double-blind, randomized, placebo-controlled clinical trial. Patients aged 6 through 25 years and with HIV infection were eligible for the study if they had blood CD4+ lymphocyte counts of <400/,ul or serum HIV p24 antigen detectable by enzyme-linked immunosorbent assay (Abbott Laboratories, Abbott Park, Ill.). Patients who had received antiviral therapy within the 2 months before the study were In contrast to the lack of effect of DTC on lymphocyte subsets, median leukocyte, neutrophil, absolute monocyte, and platelet counts were lower than those at baseline for all 24 sampling intervals in DTC-treated patients, whereas no consistent change in these cellular subsets was evident in placebotreated patients (Table 2) (P < 0.0001; Fisher's exact test). Despite the small sample size, differences between the DTC and placebo treatment groups achieved statistical significance for 3 of the 24 individual testing points during treatment (Table 2 ).
In DTC-treated patients, the median serum glucose, alkaline phosphatase, and magnesium concentrations were generally higher throughout the study period than those at baseline. These values remained relatively unchanged in placebotreated patients. DTC had no effect on serum creatinine, total bilirubin, aspartate aminotransferase, alanine aminotransferase, sodium, potassium, bicarbonate, chloride, calcium, phosphate, albumin, total protein, blood urea nitrogen, hemoglobin, or serum immunoglobulin G (IgG), IgM, or IgA levels. Consistent with the potent copper-chelating activity of DTC and animal studies (1, 10) , median serum copper levels increased in patients receiving DTC (+0.04 ,ug/ml) but decreased in those given placebo (-0.085 jxglml) (P = 0.04; rank sum test).
Among 83 skin test batteries performed (seven antigens per battery; Multitest; Connaught Laboratories, Inc., Swiftwater, Pa.), there were only eight reactions. Seven of these eight reactions were in a single patient who was treated with placebo, and none exceeded 6 mm. Two other patients reacted to histoplasmin (10 and 20 mm). Thus, 15 (79%) of 19 patients were anergic, and DTC had no effect on the skin test reactivity status.
The levels of p24 antigen increased progressively during the study for patients in both groups, with no significant betweengroup difference after 12 weeks. Opportunistic infections occurred in one DTC-treated patient (cryptococcal meningitis at NOTES (3, 6, 8) . In a French study, DTC-treated patients had decreased lymphadenopathy, fewer opportunistic infections, and increased blood CD4+ lymphocyte counts in comparison with placebo-treated patients (6) . A German study and a U.S. study each reported that DTC-treated patients were less likely than controls to develop opportunistic infections (3, 8) , although no effect on CD4`lymphocyte counts was observed. However, a second French trial involving approximately 1,300 patients indicated that DTC was associated with a faster rate of progression to AIDS (5), leading Pasteur Merieux Serums and Vaccins S. A. to close our study early. The mechanism for the increased progression to AIDS was not identified. Invariably, we observed decreases in leukocyte, neutrophil, monocyte, and platelet counts in DTC-treated subjects in our study. This apparent effect of DTC persisted for up to 4 weeks after discontinuation of the drug. Although the serum DTC half-life is only about 20 min (4), DTC produces sensitivity to alcohol for up to 2 weeks (package insert for Antabuse; Wyeth-Ayerst Laboratories, Philadelphia, Pa.) and prevented retrovirus-induced lymphoproliferation in mice for up to 6 weeks after the cessation of therapy (4) . Infrequent blood sampling and the introduction of open-label DTC and zidovudine for several patients 4 weeks after the discontinuation of DTC or placebo precluded further analysis of the posttreatment effects of DTC. Although not the primary end point of the study, the definitiveness of these findings for all three myeloid cell lines evaluated diminishes the possibility that the decreases in myeloid cell counts occurred by chance alone. Moreover, concordant with our results, ex vivo studies have reported,that DTC is toxic for human neutrophils, monocytes, and macrophages at clinically relevant concentrations (2, 9) .
Nonetheless, these novel clinical findings should be confirmed by an independent study designed specifically for this purpose.
Our results evoke concerns that DTC could decrease myelopoiesis and, consequently, immune system function, leading to increased opportunistic infections. In this regard, one could speculate that the increased progression to AIDS (5) and decreased lymphadenopathy (6) observed in DTC-treated patients in the previously published trials reflected a DTCinduced decrease in the counts of neutrophils, monocytes, and macrophages, including those in lymph nodes.
In conclusion, our findings contradict the purported ability of DTC to recruit functional lymphocytes, the principal rationale for the use of this compound in HIV infections. Moreover, future trials of DTC should include monitoring for drug-induced leukopenia, neutropenia, monocytopenia, and thrombocytopenia, especially in patient populations already at increased risk of infection. We acknowledge the assistance of Sandor Feldman, Seth Hetherington, Judith Wilimas, Winfred Wang, Marion Dugdale, Danny Lancaster, and other physicians, who provided medical care to patients who participated in this study. We thank Christy N. Wright for editorial advice.
